Search Results

There are 31801 results for: content related to: The Many vs. the Few

  1. Which Orphans Will Find a Home? The Rule of Rescue in Resource Allocation for Rare Diseases

    Hastings Center Report

    Volume 42, Issue 1, January-February 2012, Pages: 27–34, EMILY A. LARGENT and STEVEN D. PEARSON

    Article first published online : 13 JAN 2012, DOI: 10.1002/hast.12

  2. Orphan Drugs for Rare Diseases: Grounds for Special Status

    Drug Development Research

    Volume 73, Issue 3, May 2012, Pages: 115–119, Eline Picavet, Marc Dooms, David Cassiman and Steven Simoens

    Article first published online : 23 FEB 2012, DOI: 10.1002/ddr.21005

  3. Unintended effects of orphan product designation for rare neurological diseases

    Annals of Neurology

    Volume 72, Issue 4, October 2012, Pages: 481–490, Sinéad M. Murphy, Araya Puwanant, Robert C. Griggs and the Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network

    Article first published online : 29 OCT 2012, DOI: 10.1002/ana.23672

  4. You have free access to this content
    Access to orphan drugs despite poor quality of clinical evidence

    British Journal of Clinical Pharmacology

    Volume 71, Issue 4, April 2011, Pages: 488–496, Alain G. Dupont and Philippe B. Van Wilder

    Article first published online : 11 MAR 2011, DOI: 10.1111/j.1365-2125.2010.03877.x

  5. Quantitative Analysis to Guide Orphan Drug Development

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 2, August 2012, Pages: 258–261, L J Lesko

    Article first published online : 27 JUN 2012, DOI: 10.1038/clpt.2012.80

  6. You have free access to this content
    How did uncommon disorders become ‘rare diseases’? History of a boundary object

    Sociology of Health & Illness

    Volume 31, Issue 4, May 2009, Pages: 463–477, Caroline Huyard

    Article first published online : 30 MAR 2009, DOI: 10.1111/j.1467-9566.2008.01143.x

  7. Market uptake of orphan drugs – a European analysis

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 6, December 2012, Pages: 664–667, E. Picavet, L. Annemans, I. Cleemput, D. Cassiman and S. Simoens

    Article first published online : 26 JUN 2012, DOI: 10.1111/j.1365-2710.2012.01364.x

  8. The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 2, August 2012, Pages: 193–202, L D Coles and J C Cloyd

    Article first published online : 4 JUL 2012, DOI: 10.1038/clpt.2012.83

  9. You have free access to this content
    An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences

    The Milbank Quarterly

    Volume 89, Issue 3, September 2011, Pages: 450–502, AARON S. KESSELHEIM

    Article first published online : 20 SEP 2011, DOI: 10.1111/j.1468-0009.2011.00636.x

  10. You have free access to this content
    A journey of hope: lessons learned from studies on rare diseases and orphan drugs

    Journal of Internal Medicine

    Volume 260, Issue 1, July 2006, Pages: 1–10, M. WÄSTFELT, B. FADEEL and J.-I. HENTER

    Article first published online : 15 JUN 2006, DOI: 10.1111/j.1365-2796.2006.01666.x

  11. You have free access to this content
    Orphan drug legislation: lessons for neglected tropical diseases

    The International Journal of Health Planning and Management

    Volume 24, Issue 1, January/March 2009, Pages: 27–42, Stefano Villa, Amelia Compagni and Michael R. Reich

    Article first published online : 24 APR 2008, DOI: 10.1002/hpm.930

  12. Orphan drug regulations in Turkey

    Journal of Pharmaceutical Health Services Research

    Volume 4, Issue 3, September 2013, Pages: 151–153, Pelin Kılıç, Güvenç Koçkaya, Ömer Yemşen, Celil Tan, Fikriye Handan Öztunca, Pelin Aksungur and Saim Kerman

    Article first published online : 24 APR 2013, DOI: 10.1111/jphs.12018

  13. You have free access to this content
    Delayed access to treatments for rare diseases: Who's to blame?

    Respirology

    Volume 20, Issue 3, April 2015, Pages: 361–369, Karen Feltmate, Peter M. Janiszewski, Sheena Gingerich and Michael Cloutier

    Article first published online : 26 FEB 2015, DOI: 10.1111/resp.12498

  14. You have free access to this content
    The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug Space

    Drug Development Research

    Volume 75, Issue 4, June 2014, Pages: 231–234, Ashish Kumar Kakkar and Neha Dahiya

    Article first published online : 14 MAY 2014, DOI: 10.1002/ddr.21176

  15. Orphan Drugs

    Principles and Practice of Pharmaceutical Medicine, Second Edition

    Lionel D. Edwards, Andrew J. Fletcher, Anthony W. Fox, Peter D. Stonier, Pages: 265–276, 2007

    Published Online : 25 JUN 2007, DOI: 10.1002/9780470093153.ch21

  16. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

    The Journal of Clinical Pharmacology

    Volume 56, Issue 3, March 2016, Pages: 257–259, Charles Oo and Lorraine M. Rusch

    Article first published online : 18 SEP 2015, DOI: 10.1002/jcph.599

  17. You have free access to this content
    Adopting an orphan

    EMBO reports

    Volume 6, Issue 6, June 2005, Pages: 507–510, Andrea Rinaldi

    Article first published online : 1 JUN 2005, DOI: 10.1038/sj.embor.7400450

  18. Strategies for Postmarketing Surveillance of Drugs for Rare Diseases

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 3, March 2014, Pages: 265–268, A S Kesselheim and J J Gagne

    Article first published online : 5 NOV 2013, DOI: 10.1038/clpt.2013.218

  19. Rare Diseases: The Bane of Modern Society and the Quest for Cures

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 2, August 2012, Pages: 135–139, N Azie and J Vincent

    Article first published online : 27 JUN 2012, DOI: 10.1038/clpt.2012.97

  20. You have free access to this content
    Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts

    Tropical Medicine & International Health

    Volume 4, Issue 6, June 1999, Pages: 412–420, P. Trouiller, C. Battistella, J. Pinel and B. Pecoul

    Article first published online : 5 JAN 2002, DOI: 10.1046/j.1365-3156.1999.00420.x